Abstract:Under the inflammatory microenvironment of myasthenia gravis, increased serum amyloid A (SAA) promotes the differentiation of T helper cells Th1 and Th17, plasmablast cells, and plasma cells, producing acetylcholine receptor (AchR) antibodies that attack the postsynaptic membrane, leading to impaired transmission of neuromuscular junctions (created with Biorender.com). Serum amyloid A (SAA) is a clinically useful inflammatory marker involved in the pathogenesis of autoimmune diseases. This study aimed to explore the SAA levels in a cohort of patients with myasthenia gravis (MG) in relation to disease‐related clinical parameters and myasthenic crisis (MC) and elucidate the effects of SAA on immune response. A total of 82 MG patients including 50 new‐onset MG patients and 32 MC patients were enrolled in this study. Baseline data and laboratory parameters of all enrolled MG patients were routinely recorded through electronic medical systems. SAA levels were measured by enzyme‐linked immunosorbent assay (ELISA) kit. CD4+ T and CD19+ B cell subsets were analyzed by flow cytometry. In vitro, human recombinant SAA (Apo‐SAA) was applied to stimulate peripheral blood mononuclear cells (PBMCs) from MG patients to observe the effect on T and B cell differentiation. Our results indicated that SAA levels in new‐onset MG patients were higher than those in controls and were positively correlated with QMG score, MGFA classification, plasmablast cells, IL‐6, and IL‐17 levels. Subgroup analysis revealed that SAA levels were increased in generalized MG (GMG) patients than in ocular MG (OMG), as well as elevated in late‐onset MG (LOMG) than in early‐onset MG (EOMG) and higher in MGFA III/IV compared with MGFA I/II. The ROC curve demonstrated that SAA showed good diagnostic value for MC, especially when combined with NLR. In vitro, Apo‐SAA promoted the Th1 cells, Th17 cells, plasmablast cells, and plasma cells differentiation in MG PBMCs. The present findings suggested that SAA was increased in MG patients and promoted expansion of CD4+ T cell and CD19+ B cell subsets, which implicated in the severity of MG patients.

Antioxidant Status of Bilirubin and Uric Acid in Patients with Myasthenia Gravis

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

Clinical significance of serum antibodies in different types of myasthenia gravis

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Detection and Clinical Significance of Serum Autoantibodies in Patients with Myasthenia Gravis

Acupuncture and moxibustion treatment for myasthenia gravis: A systematic review and meta-analysis

Serum Bilirubin Concentrations and Multiple Sclerosis

Study of circulating Th17 cells and associated cytokines in myasthenia gravis

Insights from CD71 presentation and serum lipid peroxidation in myasthenia gravis - A small cohort study

Plasma Levels and Clinical Significance of Complement Activation Products in Generalized Myasthenia Gravis Patients with Acetylcholine Receptor Antibodies

Increase of circulating CD4 +CD25 + T cells in myasthenia gravis patients with stability and thymectomy

[Distribution Characteristics and Correlation Analysis of Antibody Detection Value in Myasthenia Gravis].

The Significance of Serum Anti-Titin Antibodies and Anti-Acetylcholine Receptor Antibodies in Patients with Myasthenia Gravis

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients

Fecal microbiota profile in a group of myasthenia gravis patients

Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host

Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions

Serum Metabolomic Profile of Myasthenia Gravis and Potential Values As Biomarkers in Disease Monitoring

Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients

Anti-presynaptic membrane receptor antibodies in myasthenia gravis.